

Astellas Announces Personnel Changes and Organization Changes

Tokyo, Japan, August 27, 2014 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced the personnel changes and organization changes as below.

1. Personnel Changes

Effective on October 1, 2014 (Current title)

Corporate Vice President, Business Development (Corporate Vice President, Licensing & Alliances)	Naoki Okamura
Vice President, Pharma Breakthrough (Vice President, Product & Portfolio Strategy)	Shigeki Kawabata
Vice President, Medical Information (Vice President, Medical Information, Japan Sales & Marketing)	Naoko Sato
General Manager, Kanetsu Branch, Japan Sales & Marketing (General Manager, Saitama Branch, Japan Sales & Marketing)	Junichi Kuwabara
General Manager, Saitama Branch, Japan Sales & Marketing (Executive Director, Chiba Branch, Japan Sales & Marketing)	Katsushi Takenaka

[Staff Executive Director]

Effective on October 1, 2014 (Current title)

Staff Executive Director, Legal & Compliance (Senior Director, Legal & Compliance)	Atsushi Kunii
---	---------------

2. Organization Changes

Licensing & Alliances

The department name of “Licensing & Alliances” in Astellas will be changed to “Business Development” effective October 1, 2014. This change will better reflect industry standards and current business development environment. The department will continue to handle licensing (in/out) and alliance for products and technologies.

Pharma Breakthrough, Product & Portfolio Strategy

In order to deliver new solutions to patients actively promoting external collaborations including those with companies outside pharmaceutical industry, “Pharma Breakthrough” group was established under Product & Portfolio Strategy in October, 2013.

Pharma Breakthrough will be the department and move directly under Astellas’ President effective October 1, 2014. This change will better demonstrate Astellas’ commitment to innovation.

Medical Information, Japan Sales & Marketing

Medical Information, currently under Japan Sales & Marketing will move directly under Astellas’ President effective October 1, 2014. This change will enhance the cooperation with internal medical-related functions and follow more transparency into the delivery system for product information to patients and customers.

###

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en